Study to evaluate safety and efficacy of induction therapy with antithymocyte-globulin and basiliximab for prevention of delayed graft function in kidney transplant recipients.
Phase of Trial: Phase IV
Latest Information Update: 01 Jul 2016
At a glance
- Drugs Basiliximab (Primary) ; Antithymocyte globulin
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 19 Aug 2015 New trial record